The disclosure provides bisindole suitable for inhibiting lipoxygenases or Αβ- formation, and treating associated diseases, such as Alzheimer's disease. The bisindoles are indolo[2,3-b]carbazole derivatives, and may be administered to a patient as part of a pharmaceutical formulation.
